Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
Type:
Grant
Filed:
August 18, 2022
Date of Patent:
June 11, 2024
Assignee:
Kymera Therapeutics, Inc.
Inventors:
Nello Mainolfi, Nan Ji, Arthur F. Kluge
Abstract: A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×109 PFU/ml) for use in therapeutic applications.
Type:
Grant
Filed:
January 10, 2022
Date of Patent:
June 11, 2024
Assignee:
Adaptive Phage Therapeutics, Inc.
Inventors:
Joseph Robert Fackler, Carl Merril, Jarrar Haider, Viet Dang
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.
Type:
Grant
Filed:
January 9, 2024
Date of Patent:
June 11, 2024
Assignees:
K2B Therapeutics, Inc., KIST (Korea Institute of Science and Technology)
Inventors:
HoWon J. Kim, In-San Kim, Jay S. Kim, Sun Hwa Kim, Ick Chan Kwon, Jong Won Lee, Yoo Soo Yang, Hong Yeol Yoon
Abstract: A method of treating or preventing a respiratory infection can include delivering aerosolized droplets of an antiviral solution to lung tissue of a subject, the antiviral solution including an aqueous carrier and an ATH conjugate that is solubilized in the aqueous carrier. The ATH conjugate includes antithrombin covalently bonded to heparin, the heparin including a polysaccharide chain having from about 15 to about 1,500 monosaccharide units.
Type:
Application
Filed:
March 25, 2022
Publication date:
June 6, 2024
Applicant:
ATH Therapeutics Inc.
Inventors:
Leslie Roy BERRY, Anthony Kam Chuen CHAN, William JACKSON, Attilio DIFIORE
Abstract: Provided herein are methods and uses of combination therapies involving a T cell therapy, e.g., a CAR T cell therapy, and a checkpoint inhibitor therapy, e.g. an anti-PD-1 antibody and/or an anti-LAG3 antibody, for treating subjects with cancers such as lymphomas, and related methods, uses, and articles of manufacture.
Type:
Application
Filed:
March 29, 2022
Publication date:
June 6, 2024
Applicant:
Juno Therapeutics, Inc.
Inventors:
Nikolaus Sebastian TREDE, Satyendra SURYAWANSHI, Shruti AGRAWAL, Shivani SRIVASTAVA, Tim PULHAM, Joe DESTEFANO, Nicolas BRAND, Ronald DUBOWY
Abstract: The present disclosure provides methods of increasing the activity of regulatory T cells (Tregs), e.g., to treat autoimmune or inflammatory diseases or disorders, using antagonist, nondepleting antibodies and antigen-binding fragments thereof that specifically bind to OX40 (e.g., human OX40).
Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.
Type:
Grant
Filed:
June 29, 2022
Date of Patent:
June 4, 2024
Assignee:
ALCRESTA THERAPEUTICS, INC.
Inventors:
Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.
Abstract: The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
June 4, 2024
Assignee:
Prevail Therapeutics, Inc.
Inventors:
Asa Abeliovich, Laura Heckman, Herve Rhinn, Li Chin Wong, Hsuan-Ni Lin, Franz Hefti
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Type:
Grant
Filed:
June 30, 2023
Date of Patent:
June 4, 2024
Assignee:
BioXcel Therapeutics, Inc.
Inventors:
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Lavanya Rajachandran, Robert Risinger
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Type:
Grant
Filed:
March 23, 2023
Date of Patent:
June 4, 2024
Assignee:
BioXcel Therapeutics, Inc.
Inventors:
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Lavanya Rajachandran, Robert Risinger
Abstract: Disclosed herein are devices, systems, and methods for ameliorating or treating or preventing Alzheimer's Disease and related dementias. Methods may include using individual patients' data to identify the optimal treatment target(s) as well as the stimulation intensity, frequency, or waveform, or any combination thereof, for transcranial electromagnetic induction delivered via a device as in the case of Transcranial Magnetic Stimulation. Systems and methods include a platform or infrastructure for treatment delivery and data processing. In some embodiments, methods are applied to restore cognitive function, ameliorate clinical symptoms, modify altered mechanisms of plasticity, modulate cortical excitability and reactivity, or induce changes in local brain metabolism.
Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
Type:
Grant
Filed:
December 7, 2022
Date of Patent:
June 4, 2024
Assignees:
Io Therapeutics, Inc., Board of Regents, The University of Texas System
Inventors:
Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Type:
Grant
Filed:
June 13, 2023
Date of Patent:
June 4, 2024
Assignee:
Sage Therapeutics, Inc.
Inventors:
Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
June 4, 2024
Assignee:
MIRATI THERAPEUTICS, INC.
Inventors:
Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
Type:
Grant
Filed:
September 26, 2023
Date of Patent:
June 4, 2024
Assignee:
ALTEROME THERAPEUTICS, INC.
Inventors:
Michael David Bartberger, Elena V. Dneprovskaia, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.
Type:
Grant
Filed:
January 6, 2023
Date of Patent:
June 4, 2024
Assignee:
APTABIO THERAPEUTICS INC.
Inventors:
Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh